Latest / The Well-Built Life / The Gut-Brain Axis: Exploring Microbial Influences on Neurology
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:24Speaker 1: and let's dive in. Imagine if your gut was communicating
- 0:27Speaker 1: directly with your brain Influencing everything from your mood to
- 0:31Speaker 1: your cognitive performance. Wouldn't that change the way you think
- 0:34Speaker 1: about health and wellness? That's exactly what the gut-brain axis
- 0:38Speaker 1: is all about.
- 0:39Speaker 2: Exactly. And it's fascinating how this idea has evolved over
- 0:43Speaker 2: the years. Let's take a step back to the early
- 0:47Speaker 2: 2000s when Dr. Sarkis K. Oskins started noticing something peculiar.
- 0:51Speaker 2: He saw patients with neurological conditions like Parkinson's disease and
- 0:56Speaker 2: autism also had guy symptoms. which initially led to the
- 1:00Speaker 2: hypothesis that maybe to raise more to the gut than
- 1:03Speaker 2: just digestion. Right.
- 1:04Speaker 1: It was a significant leap, wasn't it? Before Oskin, the
- 1:08Speaker 1: connection between the gut and the brain was more of
- 1:11Speaker 1: a scientific curiosity. But his work was groundbreaking because it
- 1:15Speaker 1: started laying out the groundwork for understanding the two-way communication
- 1:20Speaker 1: between our gut and our brain.
- 1:21Speaker 2: Yes, and by the 2010s, things took a turn for
- 1:25Speaker 2: the more nuanced. We had advancements in metabolomic screens that
- 1:29Speaker 2: identified molecules like 4-ethylphenylsulfate, EPs, which were elevated in animal models.
- 1:35Speaker 2: This started to paint a picture of the complexity involved
- 1:38Speaker 2: in how the gut and brain interact through these microbial metabolites.
- 1:42Speaker 1: That's wild when you look at the raw numbers. I mean,
- 1:46Speaker 1: can you imagine how many different chemicals and signals are
- 1:49Speaker 1: constantly being exchanged between the two systems every day? It's
- 1:54Speaker 1: like the gut is sending subtle messages to the brain.
- 1:57Speaker 1: that could be impacting everything from mood to long-term health.
- 2:00Speaker 2: Absolutely. The vagus nerve and receptor binding are key pathways here,
- 2:05Speaker 2: but it's also about inflammatory signaling. Chronic gut inflammation can
- 2:10Speaker 2: really disrupt neurochemical balance, leading to various neurological disorders. That's
- 2:15Speaker 2: why the immune system plays such a big role. It's
- 2:18Speaker 2: all interconnected, right?
- 2:19Speaker 1: Exactly. And let's not forget about the different populations of
- 2:23Speaker 1: gut bacteria. They are like little chemists creating these molecules.
- 2:28Speaker 1: Changes in the blood-brain barrier integrity can indicate the extent
- 2:31Speaker 1: of gut leakage and its impact on brain health. It's
- 2:34Speaker 1: a real balancing act.
- 2:35Speaker 2: That's true, and that's where the complexity really starts. Different
- 2:40Speaker 2: subtypes of autism might respond differently to interventions, emphasizing the
- 2:45Speaker 2: need for personalized approaches. There are just so many bacterial
- 2:50Speaker 2: species and their associated metabolic pathways. making it hard to
- 2:54Speaker 2: pinpoint specific causative agents.
- 2:56Speaker 1: So, it's all very promising, but also quite challenging. What
- 3:01Speaker 1: do you think is the biggest question researchers are currently
- 3:04Speaker 1: wrestling with?
- 3:05Speaker 2: Well, one of the biggest is identifying specific biomarkers that
- 3:09Speaker 2: can reliably track neurobiological states associated with gut-brain interactions. And
- 3:15Speaker 2: on the flip side, what are the best therapeutics to
- 3:18Speaker 2: address these issues? Probiotics and microbiomodulators are being developed. But
- 3:23Speaker 2: the challenge is translating these into effective clinical applications. Right.
- 3:27Speaker 1: And the integration of AI and machine learning could really
- 3:30Speaker 1: make a difference here. It could help in developing personalized
- 3:34Speaker 1: treatments and validating findings in human populations. It's exciting to
- 3:39Speaker 1: think about where this could go in the next few years.
- 3:42Speaker 1: Let's dive into the fascinating mechanisms of how metabolites like 4-ethylphenolsulfate, EPS,
- 3:48Speaker 1: can influence brain function via the vagus nerve. These pathways
- 3:53Speaker 1: are incredibly intricate, Thomas. How does EPS fit into this
- 3:58Speaker 1: larger picture?
- 3:59Speaker 2: Exactly. And it's crucial to understand how these microbial metabolites
- 4:03Speaker 2: interact with the vagus nerve's extensive network. Think of it
- 4:07Speaker 2: as the highway for communication between the gut and the brain.
- 4:10Speaker 2: When EPS is released into the bloodstream, it can bind
- 4:14Speaker 2: to specific nerve receptors, triggering downstream signaling processes that affect
- 4:19Speaker 2: neural function. Right.
- 4:21Speaker 1: And this isn't just a one-way street. The vagus nerve
- 4:24Speaker 1: also sends signals from the brain to the gut, modulating
- 4:27Speaker 1: gut function. This bidirectional communication could be the key to
- 4:32Speaker 1: targeted therapies for conditions like depression and anxiety. Not just
- 4:37Speaker 1: gastrointestinal disorders.
- 4:39Speaker 2: That's a great point. And to raise the inflammatory pathway
- 4:42Speaker 2: you mentioned, which is another critical component, chronic gut inflammation
- 4:46Speaker 2: can disrupt the blood-brain barrier potentially leading to neurodegenerative disorders.
- 4:51Speaker 2: In terms of autism, for example, we see elevated EPS
- 4:55Speaker 2: levels in both urine and tissue samples, suggesting a direct
- 4:59Speaker 2: link to neurodevelopmental processes.
- 5:02Speaker 1: It's not always straightforward, though. As we have talked about,
- 5:05Speaker 1: the field is full of contradictions. How do we reconcile
- 5:09Speaker 1: the clear causal links seen in mice with the more
- 5:12Speaker 1: ambiguous results in human studies?
- 5:14Speaker 2: Good question. One major challenge is the variable response in
- 5:18Speaker 2: human subjects. Different subtypes of autism might have different mechanisms
- 5:23Speaker 2: at play. The sheer number of microbial species and their
- 5:26Speaker 2: metabolic pathways complicates identifying specific causative agents. But that's also
- 5:32Speaker 2: what makes this field so exciting. Every new discovery could
- 5:36Speaker 2: unlock a whole new avenue of treatment.
- 5:38Speaker 1: Exactly. And with the integration of AI and machine learning,
- 5:42Speaker 1: we might finally be able to make sense of these
- 5:45Speaker 1: complex interactions. But let's talk about some of the practical
- 5:49Speaker 1: takeaways here. How can understanding these mechanisms help us in
- 5:53Speaker 1: our daily lives?
- 5:54Speaker 2: Well, for one, maintaining a diverse gut microbiome through diet
- 5:59Speaker 2: and probiotics could have significant cognitive benefits. And we need
- 6:04Speaker 2: to be mindful of gut health overall, as it can
- 6:07Speaker 2: impact our mental health and behavior in subtle yet profound ways.
- 6:11Speaker 1: That's a powerful reminder. It really emphasizes the importance of
- 6:15Speaker 1: self-care and holistic health. And, of course, more research is
- 6:20Speaker 1: needed to validate these findings and develop effective clinical applications.
- 6:25Speaker 2: Absolutely. But for now, the insights we have gained are
- 6:28Speaker 2: already groundbreaking. Every piece of the puzzle brings us closer
- 6:32Speaker 2: to personalized treatments that could revolutionize how we approach neurological
- 6:36Speaker 2: and psychiatric disorders.
- 6:38Speaker 1: Thomas, let's explore the intricate contradictions in this field. For instance,
- 6:43Speaker 1: how can we reconcile the clear causality shown in animal
- 6:46Speaker 1: models with the inconsistent results seen in human studies. It's
- 6:51Speaker 1: a real puzzle.
- 6:52Speaker 2: That's right, Rachel. The challenge is animal models are fantastic
- 6:56Speaker 2: tools for understanding biological mechanisms, but they don't always mirror
- 7:01Speaker 2: human physiology. There are many variables at play from the
- 7:04Speaker 2: complexity of the human microbiome to genetic diversity, which can
- 7:08Speaker 2: significantly impact outcomes.
- 7:10Speaker 1: Exactly. And while we can manipulate factors like diet and
- 7:14Speaker 1: microbial exposure in models … human subjects introduce a whole
- 7:18Speaker 1: host of additional variables. For instance, the heterogeneity in autism
- 7:23Speaker 1: subtypes complicates the issue. Different subtypes might require different interventions,
- 7:30Speaker 1: which complicates the development of a one-size-fits-all treatment.
- 7:34Speaker 2: Precisely. Take the elevation of EP's levels in human autistic
- 7:38Speaker 2: tissue and urine parallels found in animal models. While this
- 7:42Speaker 2: indicates potential biomarkers, we still lack definitive proof that it's
- 7:47Speaker 2: a causative factor in all cases. The nuances of individual
- 7:51Speaker 2: responses make it hard to draw broad conclusions.
- 7:54Speaker 1: And tarries the variability in microbial effects. Not all bacterial
- 7:59Speaker 1: species respond the same way in different individuals. Some might
- 8:03Speaker 1: produce beneficial metabolites, while others could cause harm. This adds
- 8:07Speaker 1: another layer of complexity. How do we sift through the
- 8:11Speaker 1: myriad of microbial interactions to identify the critical ones?
- 8:15Speaker 2: Right, and that's the crucial nuance here. We need to
- 8:18Speaker 2: find more reliable biomarkers that can pinpoint which particular metabolites
- 8:23Speaker 2: are key players. The challenge, of course, is that there
- 8:26Speaker 2: are hundreds of species, each with its own metabolic pathways.
- 8:30Speaker 2: It's like trying to identify a needle in a haystack.
- 8:33Speaker 1: That's wild when you look at the raw numbers. The
- 8:36Speaker 1: heterogeneity in both microbial populations and clinical presentations adds another
- 8:41Speaker 1: dimension of difficulty, but, despite all these challenges, we are
- 8:46Speaker 1: making strides. The development of targeted probiotics and microbiome modulators
- 8:51Speaker 1: is promising.
- 8:52Speaker 2: Absolutely, and the integration of AI and machine learning could
- 8:56Speaker 2: help us make sense of the data. We can use
- 8:58Speaker 2: predictive models to identify patterns and predict outcomes more accurately.
- 9:03Speaker 2: This personalized approach is crucial for addressing the complex interplay
- 9:06Speaker 2: between gut health and brain function.
- 9:08Speaker 1: Exactly. It's exciting to think about what's coming down the line.
- 9:13Speaker 1: But for now, we need to stay grounded in understanding
- 9:16Speaker 1: the fundamental mechanisms. The research is still in its early stages,
- 9:21Speaker 1: and it's essential that we continue to validate our findings
- 9:23Speaker 1: in human populations.
- 9:25Speaker 2: True. And as we do, we will likely uncover more
- 9:29Speaker 2: contradictions and debates. But that's the beauty of science continuous
- 9:34Speaker 2: exploration and refinement. We are slowly but surely unlocking the
- 9:38Speaker 2: door to a better understanding of the gut-brain axis and
- 9:42Speaker 2: its myriad effects on health.
- 9:44Speaker 1: So, let's delve into some of the key research perspectives
- 9:48Speaker 1: and unresolved questions that are shaping the future of gut-brain therapy. Thomas,
- 9:53Speaker 1: how do you see the current landscape?
- 9:55Speaker 2: Rachel, Therese a lot to unpack here. From the outset,
- 9:58Speaker 2: Therese this fascinating phenomenon debate between animal model results and
- 10:02Speaker 2: human studies. We have seen clear causality in models, but
- 10:05Speaker 2: translating that to human populations is tricky, especially with diseases
- 10:10Speaker 2: like autism where variability is high. What do you make
- 10:13Speaker 2: of that?
- 10:13Speaker 1: Exactly, and it's intriguing. The discrepancy highlights the challenges in
- 10:18Speaker 1: moving from bench to bedside. One perspective is that animal
- 10:23Speaker 1: models might not fully capture the complexity of human biology.
- 10:27Speaker 1: But that doesn't mean the insights are invalid. We just
- 10:30Speaker 1: need to refine our methodologies to better mirror human conditions.
- 10:34Speaker 2: That's a good point. Another interesting insight comes from the
- 10:37Speaker 2: work of Dr. Sarkis K. Oskun, who first observed these
- 10:41Speaker 2: GI symptoms in neurological patients. His hypothesis suggested a direct link,
- 10:46Speaker 2: which wasn't easily dismissible. How do you think his work
- 10:49Speaker 2: has influenced the current research direction?
- 10:52Speaker 1: Dr. Oskin's work was foundational. It sparked a flurry of
- 10:55Speaker 1: studies focusing on how the gut microbiome could impact the brain. Yet,
- 11:00Speaker 1: we are still grappling with identifying those causative molecules. For instance, EPS,
- 11:06Speaker 1: while promising, is just one of many potential players. How
- 11:10Speaker 1: do you see the future of EPS and other metabolites
- 11:13Speaker 1: fitting into this picture?
- 11:15Speaker 2: EPS has definitely gained traction. but it's just the tip
- 11:19Speaker 2: of the iceberg. The real challenge is understanding the broader
- 11:22Speaker 2: network of interactions. Metabolites like EPS might be key, but
- 11:26Speaker 2: we need to map out the full system. That's where
- 11:29Speaker 2: AI and machine learning come in. They can help us
- 11:32Speaker 2: process the vast datasets generated by modern research.
- 11:35Speaker 1: Precisely. And this is where the future research really gets interesting.
- 11:40Speaker 1: The idea of personalized therapies is becoming more feasible. With
- 11:44Speaker 1: better biomarkers, we can tailor treatments to specific microbial profiles.
- 11:49Speaker 1: That's a huge step forward from one-size-fits-all approaches.
- 11:53Speaker 2: Agreed. But we are not there yet. There are still
- 11:56Speaker 2: questions about which microbial communities are most beneficial and how
- 12:00Speaker 2: we can safely manipulate them without adverse effects. The ethical
- 12:04Speaker 2: considerations can't be overlooked either, especially when dealing with sensitive
- 12:08Speaker 2: areas like the brain.
- 12:09Speaker 1: Absolutely. And what about the challenges in validating these therapies
- 12:13Speaker 1: in clinical settings? It's not just about finding the right treatment,
- 12:18Speaker 1: but also ensuring it's safe and effective in real-world scenarios.
- 12:23Speaker 2: That's a critical point. We need robust, longitudinal studies that
- 12:28Speaker 2: can track patients over time. That's where big data and
- 12:32Speaker 2: advanced analytics can come to the rescue, providing a more
- 12:35Speaker 2: complete picture of the patient journey. It's a balancing act
- 12:39Speaker 2: between innovation and caution.
- 12:41Speaker 1: Definitely. The future is bright but complex. We are at
- 12:45Speaker 1: a pivotal moment where the tools and technologies are emerging,
- 12:49Speaker 1: but the path forward requires careful navigation. It's an exciting
- 12:53Speaker 1: time and one where collaboration among researchers, clinicians, and industry
- 12:58Speaker 1: players will be key. Right.
- 13:00Speaker 2: And it's not just about gut-brain therapy. It's about opening
- 13:03Speaker 2: up new avenues for treating neurological disorders. The holistic approach
- 13:07Speaker 2: to health is slowly gaining acceptance, and that's a good
- 13:11Speaker 2: sign for the field.
- 13:12Speaker 1: So, as we wrap up this discussion, Let's talk about
- 13:15Speaker 1: the strategic implications and potential breakthroughs that lie ahead in
- 13:19Speaker 1: the field of gut-brain therapy. What do you think the
- 13:23Speaker 1: most promising areas of development are? Thomas?
- 13:27Speaker 2: Right, and that's the crucial nuance here. The intersection of
- 13:30Speaker 2: AI and personalized medicine is definitely one of the most exciting. Take,
- 13:34Speaker 2: for example, the use of AI in predictive algorithms to
- 13:38Speaker 2: identify specific microbial profiles linked to particular neurological conditions. This
- 13:44Speaker 2: could really revolutionize how we tailor treatments to individual patients.
- 13:48Speaker 1: Exactly. Which brings up an interesting contradiction. While AI can
- 13:53Speaker 1: process vast amounts of data to find these correlations, there
- 13:56Speaker 1: is still a need for robust clinical trials to validate
- 13:59Speaker 1: these findings. How do we ensure these breakthroughs translate to
- 14:03Speaker 1: real-world effectiveness?
- 14:04Speaker 2: That's a great point. Clinical trials need to be meticulously
- 14:08Speaker 2: designed to capture long-term outcomes and account for variability. It's
- 14:13Speaker 2: also about maintaining the ethical standards of balance between innovation
- 14:17Speaker 2: and the safety and well-being of the patients.
- 14:19Speaker 1: Absolutely. And with personalized medicine, we are seeing more sophisticated
- 14:24Speaker 1: approaches to understanding individual patient needs, like using targeted probiotics
- 14:29Speaker 1: or microbiome modulators. Can you give an example of how
- 14:33Speaker 1: they work in practice?
- 14:35Speaker 2: Of course. Imagine a patient with irritable bowel syndrome, IBS
- 14:39Speaker 2: and associated anxiety. By analyzing their gut microbiome, we might
- 14:44Speaker 2: find a specific microbial imbalance that is contributing to their symptoms.
- 14:49Speaker 2: A personalized treatment could involve introducing specific strains of bacteria
- 14:53Speaker 2: known to counteract anxiety, improving both the gut and the brain.
- 14:58Speaker 1: Right. This multidisciplinary approach is crucial. AI can sift through
- 15:03Speaker 1: the data to identify these bacterial communities, while clinicians can
- 15:07Speaker 1: develop and test the specific interventions. It's a perfect example
- 15:11Speaker 1: of how different fields can come together to make significant progress.
- 15:15Speaker 2: Exactly. And we are already seeing initial success stories. For instance,
- 15:20Speaker 2: studies show that certain probiotics can reduce symptoms of depression
- 15:24Speaker 2: by modulating the gut microbiome. This is just scratching the surface.
- 15:29Speaker 2: As we continue to refine these approaches, the potential for
- 15:32Speaker 2: transforming treatment paradigms is immense.
- 15:35Speaker 1: Indeed. And let's not forget the broader implications for healthcare systems.
- 15:40Speaker 1: If we can move towards more personalized prophylactic treatments, it
- 15:44Speaker 1: could significantly reduce the burden on healthcare resources. AI-driven diagnostics
- 15:50Speaker 1: and therapies could make earlier interventions more feasible.
- 15:53Speaker 2: That's a wild when you look at the raw numbers.
- 15:56Speaker 2: Just consider the cost savings and improved patient outcomes. It's
- 16:00Speaker 2: a win-win. And if we can get this right, we
- 16:04Speaker 2: might be able to address neurological and psychiatric disorders in
- 16:07Speaker 2: ways we couldn't before.
- 16:09Speaker 1: Absolutely. It's a journey, but one that's full of promise.
- 16:13Speaker 1: We are at a moment where the tools are in
- 16:15Speaker 1: place to make real, tangible changes. Let's stay optimistic and
- 16:20Speaker 1: committed to pushing the boundaries of what's possible. That brings
- 16:23Speaker 1: us to the end of today's episode. Thank you so
- 16:26Speaker 1: much for spending part of your day with me. If
- 16:28Speaker 1: you found this episode's tips helpful and want to make
- 16:31Speaker 1: sure you don't miss the next conversation, please take a
- 16:34Speaker 1: quick second to hit that subscribe or follow button on
- 16:37Speaker 1: whatever platform you are listening on. It's a completely free
- 16:41Speaker 1: way to support the show and helps more people find us.
- 16:44Speaker 1: This podcast is independently produced, so if you are ever
- 16:48Speaker 1: in a position where you would like to help keep
- 16:50Speaker 1: it running, we do accept small donations. You can find
- 16:53Speaker 1: a link right in the episode description below to buy
- 16:57Speaker 1: us a coffee or contribute what you can. Every bit
- 17:00Speaker 1: genuinely helps. Take care of yourself. Stay balanced. And we
- 17:05Speaker 1: will talk again soon.